Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Aeras Stories

2014-03-24 12:29:41

Aeras releases TB Crisis Tracker on World TB Day ROCKVILLE, Md., March 24, 2014 /PRNewswire/ -- The tuberculosis epidemic continues to impact pockets of the U.S. population, according to a data visualization tool developed by the nonprofit biotech, Aeras. Launched on World TB Day, Aeras's TB Crisis Tracker illustrates how the TB epidemic continues to impact the U.S. "TB's impact in the U.S. is but a fraction of what it once was, but the Aeras TB Crisis Tracker starkly...

2013-11-18 23:21:06

Reportbuyer.com just published a new market research report: Tuberculosis Global Clinical Trials Review, H2, 2013. (PRWEB) November 18, 2013 Summary GlobalData's clinical trial report, “Tuberculosis Global Clinical Trials Review, H2, 2013" provides data on the Tuberculosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tuberculosis. It includes an overview of the trial numbers and their recruitment status as per...

2013-11-07 20:21:58

TOKYO and NEW YORK, Nov. 7, 2013 /PRNewswire-USNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease. "Our six new investments in potential treatments for malaria, tuberculosis and...

Tuberculosis Vaccine Shows Promising Results
2013-10-03 04:39:56

redOrbit Staff & Wire Reports - Your Universe Online Canadian researchers have developed a new tuberculosis vaccine that could boost or perhaps replace the only existing way to immunize against the infection. The researchers say the new vaccine is an important breakthrough because the current tuberculosis vaccine is not effective enough to curb the TB epidemic in some parts of the world. "We are the first to have developed such a vaccine for tuberculosis," said Dr. Fiona Smaill,...

2013-03-06 04:22:34

ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship. Gerd Zettlmeissl has more than 20 years of experience in developing and commercializing...

Tuberculosis Vaccine Fails Infant Trial
2013-02-04 14:42:30

[ Watch the Video: Discussing New Tuberculosis Vaccine Trials ] Lee Rannals for redOrbit.com - Your Universe Online A new vaccine considered to be the most advanced for tuberculosis (TB) among more than a dozen now in trials has failed its study. Researchers said they were disappointed by the results of the study, which showed that the vaccine offered little to no protection at all from TB. Nearly 3,000 babies in South Africa took part in the study, all of whom had already been...

2012-11-14 08:32:23

GAITHERSBURG, Md., Nov. 14, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 61st Annual Meeting, which took take place in Atlanta, Georgia on November 11-15, 2012. Data presented at the conference highlighted GenVec's success in identifying novel antigens for use in its malarial vaccine development program. Using a proprietary screening...

2012-10-09 23:20:19

Phase IIb Proof of Concept Trial Planned for Kenya, India and South Africa ROCKVILLE, Md., Oct. 10, 2012 /PRNewswire-USNewswire/ -- Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01(E)(*) adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and one...

2012-08-22 06:24:25

Phase I study in Lenexa, KS, of novel vaccine targeting TB virulence and latency ROCKVILLE, Md. and SEATTLE, Aug. 22, 2012 /PRNewswire-USNewswire/ -- Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be...

2012-05-09 06:26:18

First Phase I study of vaccine candidate planned for this year ROCKVILLE, Md. and SEATTLE, May 9, 2012 /PRNewswire-USNewswire/ -- Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI's novel tuberculosis vaccine candidate. This collaboration reflects the missions of the two non-profit product development partnerships to use cutting-edge science to develop products that address critical...